GLPBio

Remacemide

Catalog No.: GC73886Synonyms: FPL 12924; PR 934-423; FPL 13592
COASDSData Sheet
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist.

Products are for research use only. Not for human use. We do not sell to patients.

Remacemide
Cas No.: 128298-28-2
5 mgIn Stock
$149.00
1
10 mgIn Stock
$239.00
1
25 mgIn Stock
$477.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of poxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research.

References:
[1]. Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9(4):871-83.
[2]. Dyker AG, et al. Remacemide drochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30(9):1796-801.
[3]. Greenamyre JT, et al. Antiparkinsonian effects of remacemide drochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35(6):655-61.
[4]. Kieburtz K, et al. A controlled trial of remacemide drochloride in Huntington's disease. Mov Disord. 1996 May;11(3):273-7.

Product Documents

Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
128298-28-2
Synonyms
FPL 12924; PR 934-423; FPL 13592
Molecular Formula
C17H20N2O
Molecular Weight
268.35
Solubility
DMSO : 87.5 mg/mL (326.07 mM; Need ultrasonic)
Storage
-20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Remacemide

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%